All problems
pharma
Your UK launch strategy isn't translating to uptake
"We had strong trial data and a credible value dossier, but six months post-launch our uptake figures were nowhere near forecast. We didn't have the right people with the right relationships in the right place."
Takes two minutes. A free, no-obligation chat with Solva.
- A UK launch that misses ICB formulary listing in the first six months will typically lose 18 to 24 months of prescribing momentum, even after listing is secured
- Engaging a UK commercial access lead with existing ICB relationships reduces time-to-formulary by an average of 30%
- Clinical champion programmes in the top 20 NHS trusts account for the majority of early uptake in most specialty indications
- Revenue significantly below forecast in year one
- Loss of first-mover advantage to competitors
- Board confidence in UK commercial team erodes
- Resource reallocation away from the product
- Patient access delayed in priority indications
Frequently asked questions
Why does this problem persist?
NICE approval is treated as the finish line rather than the starting gun Local formulary and ICB decision-making timelines are underestimated Field teams lack the payer and pathway knowledge to engage effectively
What is the cost of leaving it unaddressed?
A product achieving 40% of year-one uptake forecast loses an estimated 60% of projected annual revenue until access is corrected.
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.